资源描述：
《利克飞龙抑制实验性脉络膜新生血管中COX-2表达的研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、利克飞龙抑制实验性脉络膜新生血管中VEGF表达的研究*党维华，于沛涛，吕玲，徐丽摘要目的观察利克飞龙抑制实验性脉络膜新生血管(CNV)中VEGF表达的作用。方法42只无眼疾C57BL/6小鼠，随机分成7组，正常对照组、激光过量光凝后3、7、21天光凝组、利克飞龙组，光凝一周前经口灌胃给药，60mg/kg,1次/天，至实验结束，其它同光凝组。正常对照组激光光凝前取标本，光凝组和利可飞龙组激光光凝后3、7、21天取标木。经免疫组化染色，采用CMIS-2011细胞医学图像分析系统对染色的平均灰度值进行测定。结果激光光凝后3、7、21天表达逐渐增强，21天表达最多。利克飞龙组与光凝组比
2、较，激光光凝后3天两组间差异无统计学意义(P〉0・05),光凝后7.21天差异有统计学意义(P〈0・05),利克飞龙组在7、21天VEGF表达明显低于光凝组。结论利克飞龙能抑制实验性CNV中VEGF的表达，有望成为CNV治疗的新方法。关键词利克飞龙实验性脉络膜新生血管血管内皮生长因子LicofeloneinhibittheexpressionofVEGFinexperimentalchoroidalneovascolarizationDANGWei-hua,YUPei-tao,LVLing,XULiOphthalmology,Shen^houHospitalAffiliated
3、toShenyangMedicalCollege,Shenyang110002,ChinaCorrespondingauthor:YUPei-tao,PekingUniversitySchoolofBasicMedicalSciences,BeijingI0019I,China,Email:yupeitao@126.comAbstractObjectiveToobservelicofeloneinhibittheexpressionofVEGFinexperimentalchoroidalneovascolarization(CNV)•Method42C57BL/6micewe
4、rerandomlydividedintonormalcontrolgroup,thelaserphotocoagulationgroup,licofelonetreatmentgroup,laserphotocoagulationgroupwithexcessivemulti-wavelengthkryptonionlaserphotocoagulationinducedchoroidalneovasculatization,licofelonegroup,oneweekbeforelaserphotocoagulation,bygavage,thedosefor60mg/k
5、gonceaday,untiltheendoftheexperiment.Normalcontrolgroupinthespecimensbeforephotocoagulation,photocoagulationgroupandthelicofelonetreatmentgroupat3>7、21daysafterphotocoagulationthespecimens.VEGFimmunohistochemicalstaining,theuseoftheCMIS-2011cellsstainedmedicalimageanalysissystemthemeangrayva
6、lueofVEGFpositivestainingtobemeasured.ResultsAfterphotocoagulation3、7、21daysofVEGFexpressiongraduallyincreased,expressionupto21days,licofelonegroupphotocoagulationgroupatthesametimepoint,3daysthetwogroupsnosignificantdifferencewasnotstatisticallysignificant(P>0.05),in7、21daysVEGFpositiveexpr
7、essionthansimplyreducethephotocoagulationgroup,thedifferencewasstatisticallysignificant(P<0.05)-ConclusionsLicofelonecanreducetheexpressionofVEGFinthelaserinducedchoroidalneovascularization,expectedtobecomeanewtherapeuticapproachintreatmentofCNV.Ke
